.

Deeper Knowledge, Faster

  • Find suppliers and generic API sources
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Baxter
Deloitte
Dow
McKinsey
Daiichi Sankyo
Moodys
Merck
Boehringer Ingelheim
Colorcon

Generated: June 29, 2017

DrugPatentWatch Database Preview

Teduglutide recombinant - Generic Drug Details

« Back to Dashboard

What are the generic drug sources for teduglutide recombinant and what is the scope of teduglutide recombinant patent protection?

Teduglutide recombinant
is the generic ingredient in one branded drug marketed by Nps Pharms Inc and is included in one NDA. There are twelve patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Teduglutide recombinant has seventy-five patent family members in eighteen countries.

There is one drug master file entry for teduglutide recombinant. One supplier is listed for this compound.

Summary for Generic Name: teduglutide recombinant

Tradenames:1
Patents:12
Applicants:1
NDAs:1
Drug Master File Entries: see list1
Suppliers / Packagers: see list1
Clinical Trials: see list1,506
Formulation / Manufacturing:see details
Drug Prices:see low prices
DailyMed Link:teduglutide recombinant at DailyMed

Pharmacology for Ingredient: teduglutide recombinant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes► Subscribe► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes7,056,886► SubscribeY ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes9,545,434► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes9,572,867► Subscribe ► Subscribe
Nps Pharms Inc
GATTEX KIT
teduglutide recombinant
POWDER;SUBCUTANEOUS203441-001Dec 21, 2012RXYesYes9,539,310► Subscribe ► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Generic Ingredient: teduglutide recombinant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,049,284Glucagon-like peptide-2 and its therapeutic use► Subscribe
7,888,317Glucagon-like peptide-2 and its therapeutic use► Subscribe
5,834,428 Glucagon-like peptide-2 and its therapeutic use► Subscribe
6,184,201 Intestinotrophic glucagon-like peptide-2 analogs► Subscribe
8,846,625Glucagon-like peptide-2 analogs► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Ingredient: teduglutide recombinant

Country Document Number Estimated Expiration
Canada2395814► Subscribe
Cyprus2615► Subscribe
Japan2008518941► Subscribe
European Patent Office1231219► Subscribe
Japan4496183► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Tradename: TEDUGLUTIDE RECOMBINANT

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2013 00012Denmark► Subscribe
3Finland► Subscribe
153Luxembourg► SubscribePRODUCT NAME: TEDUGLUTIDE SOUS TOUTES SES FORMES, TELLES QU ELLES SONT PROTEGEES PAR LE BREVET DE BASE
90009-7Sweden► SubscribePRODUCT NAME: TEDUGLUTID; REG. NO/DATE: EU/1/12/787/001 20120830
00578Netherlands► SubscribePRODUCT NAME: TEDUGLUTIDE OR A PHARMACEUTICALLY ACCEPTABLE FORM THEREOF; REGISTRATION NO/DATE: EU/1/12/787/001 20120830
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

US Army
Accenture
Medtronic
Chubb
Julphar
Citi
Johnson and Johnson
Covington
Harvard Business School
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot